Literature DB >> 32058031

Role of lipids in pathophysiology, diagnosis and therapy of hepatocellular carcinoma.

Christa Buechler1, Charalampos Aslanidis2.   

Abstract

Hepatocellular carcinoma (HCC) is an aggressive and widespread cancer. Patients with liver cirrhosis of different aetiologies are at a risk to develop HCC. It is important to know that in approximately 20% of cases primary liver tumors arise in a non-cirrhotic liver. Lipid metabolism is variable in patients with chronic liver diseases, and lipid metabolites involved therein do play a role in the development of HCC. Of note, lipid composition of carcinogenic tissues differs from non-affected liver tissues. High cholesterol and low ceramide levels in the tumors protect the cells from oxidative stress and apoptosis, and do also promote cell proliferation. So far, detailed characterization of the mechanisms by which lipids enable the development of HCC has received little attention. Evaluation of the complex roles of lipids in HCC is needed to better understand the pathophysiology of HCC, the later being of paramount importance for the development of urgently needed therapeutic interventions. Disturbed hepatic lipid homeostasis has systemic consequences and lipid species may emerge as promising biomarkers for early diagnosis of HCC. The challenge is to distinguish lipids specifically related to HCC from changes simply related to the underlying liver disease. This review article discusses aberrant lipid metabolism in patients with HCC.
Copyright © 2020 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Ceramide; Cholesterol; Fatty acid; MELD score; Phospholipids

Year:  2020        PMID: 32058031     DOI: 10.1016/j.bbalip.2020.158658

Source DB:  PubMed          Journal:  Biochim Biophys Acta Mol Cell Biol Lipids        ISSN: 1388-1981            Impact factor:   4.698


  13 in total

1.  Didymin Ameliorates Liver Fibrosis by Alleviating Endoplasmic Reticulum Stress and Glycerophospholipid Metabolism: Based on Transcriptomics and Metabolomics.

Authors:  Yan Li; Cuiyu Li; Yuhua Xiong; Bin Fang; Xing Lin; Quanfang Huang
Journal:  Drug Des Devel Ther       Date:  2022-06-07       Impact factor: 4.319

2.  Two Metabolomics Phenotypes of Human Hepatocellular Carcinoma in Non-Alcoholic Fatty Liver Disease According to Fibrosis Severity.

Authors:  Benjamin Buchard; Camille Teilhet; Natali Abeywickrama Samarakoon; Sylvie Massoulier; Juliette Joubert-Zakeyh; Corinne Blouin; Christelle Reynes; Robert Sabatier; Anne-Sophie Biesse-Martin; Marie-Paule Vasson; Armando Abergel; Aicha Demidem
Journal:  Metabolites       Date:  2021-01-14

3.  Hepatic lipid profile in mice fed a choline-deficient, low-methionine diet resembles human non-alcoholic fatty liver disease.

Authors:  Elisabeth M Haberl; Rebekka Pohl; Lisa Rein-Fischboeck; Marcus Höring; Sabrina Krautbauer; Gerhard Liebisch; Christa Buechler
Journal:  Lipids Health Dis       Date:  2020-12-09       Impact factor: 3.876

Review 4.  Involvement of LDL and ox-LDL in Cancer Development and Its Therapeutical Potential.

Authors:  Chang-Feng Deng; Neng Zhu; Tan-Jun Zhao; Hong-Fang Li; Jia Gu; Duan-Fang Liao; Li Qin
Journal:  Front Oncol       Date:  2022-02-16       Impact factor: 6.244

5.  Accumulation of cholesterol, triglycerides and ceramides in hepatocellular carcinomas of diethylnitrosamine injected mice.

Authors:  Elisabeth M Haberl; Rebekka Pohl; Lisa Rein-Fischboeck; Marcus Höring; Sabrina Krautbauer; Gerhard Liebisch; Christa Buechler
Journal:  Lipids Health Dis       Date:  2021-10-10       Impact factor: 3.876

Review 6.  Emerging Insights on the Diverse Roles of Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) in Chronic Liver Diseases: Cholesterol Metabolism and Beyond.

Authors:  Thomas Grewal; Christa Buechler
Journal:  Int J Mol Sci       Date:  2022-01-19       Impact factor: 5.923

7.  Navigating through the Lipid Metabolism Maze: Diagnosis and Prognosis Metabolites of Hepatocellular Carcinoma versus Compensated Cirrhosis.

Authors:  Iuliana Nenu; Horia Stefanescu; Bogdan Procopet; Zeno Sparchez; Iulia Minciuna; Tudor Mocan; Daniel Leucuta; Corina Morar; Mircea Grigorescu; Gabriela Adriana Filip; Carmen Socaciu
Journal:  J Clin Med       Date:  2022-02-26       Impact factor: 4.241

8.  Hepatocyte expressed chemerin-156 does not protect from experimental non-alcoholic steatohepatitis.

Authors:  Rebekka Pohl; Laura Eichelberger; Susanne Feder; Elisabeth M Haberl; Lisa Rein-Fischboeck; Nichole McMullen; Christopher J Sinal; Astrid Bruckmann; Thomas S Weiss; Michael Beck; Marcus Höring; Sabrina Krautbauer; Gerhard Liebisch; Reiner Wiest; Josef Wanninger; Christa Buechler
Journal:  Mol Cell Biochem       Date:  2022-04-21       Impact factor: 3.842

9.  Effect of Oxidized Low-Density Lipoprotein on Head and Neck Squamous Cell Carcinomas.

Authors:  Nadège Kindt; Fabrice Journé; Stéphane Carlier; Anne Trelcat; Alessandro Scalia; Sven Saussez
Journal:  Biomedicines       Date:  2021-05-05

10.  Liver Lipids of Patients with Hepatitis B and C and Associated Hepatocellular Carcinoma.

Authors:  Elisabeth M Haberl; Thomas S Weiss; Georg Peschel; Kilian Weigand; Nikolai Köhler; Josch K Pauling; Jürgen J Wenzel; Marcus Höring; Sabrina Krautbauer; Gerhard Liebisch; Christa Buechler
Journal:  Int J Mol Sci       Date:  2021-05-18       Impact factor: 5.923

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.